Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188064 | Vitamin D analogs for obesity prevention and treatment Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihyd... | 05/29/2012 |
| 8188065 | Boldine compounds for promoting bone growth The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disea... | 05/29/2012 |
| 8178517 | 6-methylvitamin Danalogs and their uses This invention discloses 6-methylvitamin D3 analogs, and specifically 1α,25-dihydroxy-6-methylvitamin D3, and pharmaceutical uses therefor. This compound exhibits vitamin D receptor binding activity and transcription activity as well as activi... | 05/15/2012 |
| 8168618 | Emulsifying agent The present invention has its object to provide a novel emulsifier which is obtainable from an edible yeast and is highly safe and shows by itself a high level of emulsifying property and high emulsion stability; a water-soluble composition containing a liposoluble ... | 05/01/2012 |
| 8143239 | Composition for inhalation The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000. ... | 03/27/2012 |
| 8143238 | Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin D compound Methods of increasing the thickness of the epidermal layer in the skin of a human comprising topically administering a therapeutically effective dose of an active pharmaceutical ingredient comprising a vitamin D analog including 2-methylene-19-nor-20(S)-1α-hydroxy-... | 03/27/2012 |
| 8114859 | 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arrest... | 02/14/2012 |
| 8106035 | 25-SO-substituted analogs of 1μ,25-dihydroxyvitamin D The present invention provides novel D-ring and side-chain analogs of 1α,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention ... | 01/31/2012 |
| 8093232 | 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferen... | 01/10/2012 |
| 8058265 | 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analog... | 11/15/2011 |
| 8030295 | 19,26,27-trinor-1α,25-dihydroxyvitamin Dcompounds Compounds of formula 1 are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups, and R1 and R2 have the definitions provided herein. Such compounds may be used in preparin... | 10/04/2011 |
| 7985744 | Vitamin D derivatives The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalcemic effect. The presen... | 07/26/2011 |
| 7973024 | 24-sulfoximine vitamin Dcompounds The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modul... | 07/05/2011 |
| 7947666 | 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the prol... | 05/24/2011 |
| 7943601 | 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D3, and pharmaceutical uses therefore. This compound exhibits activity in arrestin... | 05/17/2011 |
| 7915242 | Vitamin D receptor antagonists and their use in treating asthma Various compounds such as those having the formula I and XIV where the variables have the values described herein antagonize the vitamin D receptor and are useful in treating conditions such as asthma and in preparing medicaments for use in antagonizing the vitamin ... | 03/29/2011 |
| 7915241 | Preparation of 24 alkyl analogs of cholecalciferol and non-racemic compounds Disclosed is a process for the preparation of 24-alkyl analogs of cholecalcyferol of Formula 1 having a (5E) or (5Z) configuration, wherein X represents a hydrogen atom, a hydroxy group or an OR1 group, where R1, R2 and R3 | 03/29/2011 |
| 7906496 | Carboxylic acid derivatives The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxy, sulfhydryl, amino or imino compounds, and to compositions containing them... | 03/15/2011 |
| 7906495 | Monohalogenovinyl vitamin D derivative compounds New vitamin D derivative compounds containing a monohalovinyl moiety at position C-20 are described. A process for obtaining the new compounds, consisting of reacting an aldehyde precursor with a haloform in the presence of Cr2+ salts, is also desc... | 03/15/2011 |
| 7893043 | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high tr... | 02/22/2011 |
| 7888338 | 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethy... | 02/15/2011 |
| 7888339 | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as... | 02/15/2011 |
| 7879829 | 19-nor-vitamin D analogs with 1,2-dihydrofuran ring 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them thera... | 02/01/2011 |
| 7858602 | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in th... | 12/28/2010 |
| 7803789 | Vitamin D analog—RAK, methods and uses thereof Compounds of formula IA or IB are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups and R1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms;... | 09/28/2010 |
| RE41491 | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the mono... | 08/10/2010 |
| RE41474 | (20S)-1α-Hydroxy-2-Methylene-19-Nor-Bishomopregnacalciferol and its uses This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the mono... | 08/03/2010 |
| 7763599 | Modified retinoid compounds and their uses A method of minimizing or reducing the toxicity of a retinoid having a free carboxyl group and the resulting modified retinoids are described. The method comprises the step of esterifying the carboxyl group of the retinoid with a highly sterically hindered compound,... | 07/27/2010 |
| 7763598 | 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells a... | 07/27/2010 |
| 7759328 | Composition for inhalation The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000. ... | 07/20/2010 |
| 7749986 | Homogeneously formulating microdosed active principles A microdose of at least one active principle is homogeneously formulated as an ointment using a container with perforations having a size and shape that permit diffusion of the active principle(s) and petroleum jelly through the perforations, by: (a) weighing the at... | 07/06/2010 |
| 7741313 | 17,20(E)-dehydro vitamin D analogs and their uses This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o... | 06/22/2010 |
| 7741314 | 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs This invention discloses 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20R,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arrest... | 06/22/2010 |
| 7718636 | Use of 2-methylene-19-nor-20(S)-1alpha,25dihydroxy vitamin d3 to inhibit mammary tumor This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. Administration of this compound increases the life expectancy of human beings, especially elderly human beings. In particular, it increases the survival r... | 05/18/2010 |
| 7718638 | (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20R)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronoun... | 05/18/2010 |
| 7718637 | (20S)-23,23-difluoro-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronoun... | 05/18/2010 |
| 7713953 | 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D3, and pharmaceutical us... | 05/11/2010 |
| 7713951 | 2-alkylidene-18,19-dinor-vitamin D compounds 2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transpo... | 05/11/2010 |
| 7713952 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferat... | 05/11/2010 |
| 7704982 | 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and its uses This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undiffere... | 04/27/2010 |
